References
- Surveillance Epidemiology and End Results (SEER) Program. Cancer stat facts: lung and bronchus cancer; 2020; [cited 2020 Jun 15]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html
- American Cancer Society. Key statistics for lung cancer; 2020; [cited 2020 Jun 15]. Available from: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
- Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–644.
- Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850–859.
- Paik PK, Drilon A, Fan P-D, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842–849.
- Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11(9):1493–1502.
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–550.
- Vuong HG, Ho ATN, Altibi AMA, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – a systematic review and meta-analysis. Lung Cancer. 2018;123:76–82.
- Novartis Pharmaceuticals. Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14; 2020; [cited 2020 Jul 16]. Available from: https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-met-inhibitor-tabrecta-metastatic-non-small-cell-lung-cancer-metex14
- Hsu F, De Caluwe A, Anderson D, et al. Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. Curr Oncol. 2017;24(4):228–233.
- Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96–102.
- United States Food and Drug Administration. Highlights of prescribing information: TABRECTA (capmatinib); 2020; [cited 2020 Jul 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf
- Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–957.
- National Comprehensive Cancer Network. Non-small cell lung cancer guidelines (version 5); 2019; [cited 2020 Mar 19]. Available from: https://pubmed.ncbi.nlm.nih.gov/28404761/
- National Comprehensive Cancer Network. Non-small cell lung cancer guidelines (version 6); 2020; [cited 2020 Aug 4]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
- United States Bureau of Labor Statistics. Consumer price index – all urban consumers, not seasonally adjusted US city average for medical care, 2006–2019; 2019; [cited 2019 Sep 16]. Available from: http://download.bls.gov/pub/time.series/cu/cu.data.15.USMedical
- Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health. 2007;10(5):336–347.
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14.
- United States Census Bureau. Health insurance coverage in the United States: 2018; 2019; [cited 2019 Nov 11]. Available from: https://www.census.gov/content/dam/Census/library/publications/2019/demo/p60-267.pdf
- The Henry J. Kaiser Family Foundation. An overview of Medicare; 2019; [cited 2019 Nov 11]. Available from: https://www.kff.org/medicare/issue-brief/an-overview-of-medicare/
- Surveillance Epidemiology and End Results (SEER) Program. Prevalence database: US estimated complete prevalence (including counts) by age on 1/1/2016; 2016; [cited 2019 Sep 5]. Available from: https://surveillance.cancer.gov/prevalence/canques.html
- Surveillance Epidemiology and End Results (SEER) Program. Cancer stat facts: lung and bronchus cancer; 2016; [cited 2019 Nov 11]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html#survival
- IBM Micromedex. RED BOOK; 2019; [cited 2019 Apr 9]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/
- Centers for Medicare & Medical Services. April 2020 ASP pricing file; 2020; [cited 2020 Mar 16]. Available from: https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2020-asp-drug-pricing-files
- Centers for Medicare & Medical Services. CMS physician fee schedule; 2019; [cited 2019 Sep 10]. Available from: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx
- Huang M, Lopes GL, Insinga RP, et al. Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA. Immunotherapy. 2019;11(17):1463–1478.
- Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047.
- Centers for Medicare & Medical Services. CMS clinical laboratory fee schedule 2020 Q1 2020; 2020; [cited 2020 Mar 6]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files.html
- Agency for Healthcare Research and Quality. Healthcare cost and utilization project (HCUP); 2016; [cited 2019 Oct]. Available from: https://hcupnet.ahrq.gov/#setup
- Skinner KE, Fernandes AW, Walker MS, et al. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. J Med Econ. 2018;21(2):192–200.
- Novartis Pharmaceuticals. A phase II, multicenter study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt) advanced non-small cell lung cancer (NSCLC). Clinical study report; 2019.
- Bittoni MA, Arunachalam A, Li H, et al. Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for Medicare patients 65 years and older with advanced non-small-cell lung cancer: a retrospective study. Clin Lung Cancer. 2018;19(5):e629–e645.
- Dalal AA, Guerin A, Mutebi A, et al. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. J Med Econ. 2018;21(7):649–655.
- Gong J, Pan K, Fakih M, et al. Value-based genomics. Oncotarget. 2018;9(21):15792–15815.
- Velcheti V, Patwardhan PD, Liu FX, et al. Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States. PLoS One. 2018;13(11):e0206370.
- Kim JH, Kim HS, Kim BJ. Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis. J Cancer. 2018;9(10):1836–1845.
- Guo B, Cen H, Tan X, et al. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. PLoS One. 2014;9(6):e99399.